Coherus Oncology auditor Ernst & Young agrees with Item 4.01 disclosure
Ernst & Young LLP confirmed agreement with statements in Coherus Oncology's Form 8-K Item 4.01 filing dated June 12, 2026, regarding an auditor change. The filing indicates a transition in the company's external audit relationship.
View filing at SEC.gov →